Basket | Login | Register

 
 
 
 

Actinogen Medical announces results from its Phase II clinical trial XanADu in AD

Tuesday 07 May 2019

On 7 May, the Australian biotechnology company Actinogen Medical developing innovative treatments for Alzheimer’s disease (AD) and the cognitive impairment associated with neurodegenerative diseases, announced results from its Phase II clinical trial XanADu of Xanamem, which is a drug candidate targeting excess brain cortisol. The Phase II trial is a double-blind, randomised and placebo-controlled study investigating the safety, tolerability and efficacy of Xanamem (10 mg daily) in people with mild dementia due to AD.  XanADu started recruitment in 2017 and enrolled 186 participants across Australia, UK and USA.

Initial data showed that a 10 mg daily dose of Xanamem is safe and can inhibit cortisol production. However, the experimental drug had not demonstrated efficacy in improving cognition. The primary and secondary endpoint measures failed to demonstrate statistical differences between Xanamem (10 mg) and placebo. The company pursues studies which are evaluating Xanamem at higher doses (20 and 30 mg). Results are expected by end of June.

https://actinogen.com.au/wp-content/uploads/2019/05/20190507-ASX-1927475-Phase-II-Alzheimers-Disease-Trial-results.pdf

Options